What's Actually in Mounjaro: The Complete Ingredient Breakdown and Why It Matters

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro contains one active ingredient (tirzepatide) and seven inactive ingredients that control pH, stability, and injection comfort
• The active dose ranges from 2.5 mg to 15 mg per injection, but the total solution volume stays constant at 0.5 mL
• Compounded tirzepatide uses the same active ingredient but different inactive components, which can affect reconstitution stability and injection site reactions
• The polysorbate 80 in brand-name Mounjaro prevents protein aggregation but is the most common allergen in the formulation

Direct answer (40-60 words)

Mounjaro contains tirzepatide as its single active ingredient, available in doses from 2.5 mg to 15 mg per 0.5 mL injection. The seven inactive ingredients (sodium chloride, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, polysorbate 80, hydrochloric acid, sodium hydroxide, and water for injection) control pH, prevent degradation, and maintain solution stability.

Table of contents

1. The complete ingredient list: active and inactive
2. What tirzepatide actually is and how it works
3. The inactive ingredients and what each one does
4. Why the same dose takes up the same volume across all strengths
5. What most articles get wrong about "fillers"
6. How compounded tirzepatide formulations differ
7. The polysorbate 80 question: necessary stabilizer or avoidable allergen?
8. Ingredients that are NOT in Mounjaro (and why that matters)
9. The pH balance: why Mounjaro sits at 7.4
10. Storage requirements and how ingredients affect stability
11. When ingredients matter for side effects
12. FAQ

The complete ingredient list: active and inactive

Mounjaro's FDA-approved formulation contains exactly eight ingredients. One is active (the drug that produces the therapeutic effect). Seven are inactive (excipients that keep the active ingredient stable, safe to inject, and comfortable).

Active ingredient:

• Tirzepatide: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL dose

Inactive ingredients (identical across all dose strengths):

• Sodium chloride: 4.1 mg
• Sodium phosphate dibasic heptahydrate: 0.74 mg
• Sodium phosphate monobasic monohydrate: 0.11 mg
• Polysorbate 80: 0.04 mg
• Hydrochloric acid (quantity sufficient to adjust pH)
• Sodium hydroxide (quantity sufficient to adjust pH)
• Water for injection (quantity sufficient to 0.5 mL)

The formulation is standardized. A 2.5 mg pen and a 15 mg pen contain the same inactive ingredients in the same amounts. The only variable is the tirzepatide concentration.

This is the complete list as published in the Mounjaro prescribing information (Eli Lilly, updated December 2025). No other ingredients are present. No preservatives, no benzyl alcohol, no metacresol (common in insulin formulations but absent here).

What tirzepatide actually is and how it works

Tirzepatide is a synthetic peptide, specifically a 39-amino-acid sequence engineered to activate two receptor types: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It's the first dual agonist approved for weight loss.

The molecular weight is 4,813 daltons. The chemical formula is C₂₂₅H₃₄₈N₅₆O₆₈. It's manufactured through recombinant DNA technology in modified E. coli bacteria, then purified through multiple chromatography steps to pharmaceutical grade (greater than 98% purity per the European Medicines Agency assessment report, 2022).

The mechanism is receptor binding. When tirzepatide binds to GLP-1 receptors in the pancreas, gut, and brain, it triggers insulin release (when glucose is present), slows gastric emptying, and reduces appetite signaling in the hypothalamus. The GIP receptor activation adds additional insulin secretion and may improve fat metabolism, though the GIP contribution to weight loss is still debated in the literature.

The half-life is approximately 5 days (Urva et al., Clinical Pharmacokinetics, 2022), which allows once-weekly dosing. The peptide is eventually broken down by proteolytic enzymes into inactive amino acid fragments and cleared through normal protein metabolism pathways.

Tirzepatide is not a small molecule like metformin or a modified hormone like insulin. It's a designed peptide that mimics natural incretin hormones but with structural modifications that extend its duration of action.

The inactive ingredients and what each one does

Inactive ingredients are not inert. Each serves a specific pharmaceutical function. Here's what the seven excipients in Mounjaro actually do:

Sodium chloride (4.1 mg): Creates isotonicity. An isotonic solution has the same osmotic pressure as blood and tissue fluid, which prevents cell damage at the injection site. Without sodium chloride, the solution would be hypotonic and cause red blood cells to swell and potentially rupture when injected. The 4.1 mg amount brings the solution to approximately 290 mOsm/kg, matching physiological osmolality.

Sodium phosphate dibasic heptahydrate (0.74 mg) and sodium phosphate monobasic monohydrate (0.11 mg): These are the pH buffer system. Together they create a phosphate buffer that holds the solution at pH 7.4 (physiological pH). Tirzepatide is most stable and least prone to aggregation at neutral pH. If the pH drifts below 6.5 or above 8.0, the peptide begins to unfold and aggregate into inactive clumps. The buffer prevents that drift during storage.

Polysorbate 80 (0.04 mg): A nonionic surfactant that prevents protein aggregation. Peptides like tirzepatide have hydrophobic regions that want to stick together, especially during shipping vibration or temperature fluctuation. Polysorbate 80 coats the peptide molecules and keeps them separated in solution. This is critical for maintaining dose accuracy. Without it, tirzepatide would precipitate out of solution as visible particles, making the drug unsafe to inject.

Polysorbate 80 is also the most common allergen in the formulation. Patients with polysorbate allergies (rare, but documented) cannot use Mounjaro and need a compounded formulation without it.

Hydrochloric acid and sodium hydroxide (quantity sufficient): pH adjusters. During manufacturing, the solution is tested and microdosed with HCl (to lower pH) or NaOH (to raise pH) until it hits exactly 7.4. The "quantity sufficient" designation means the amount varies batch to batch depending on what's needed. Typical amounts are in the microgram range.

Water for injection (WFI): Sterile, pyrogen-free water that meets USP standards. Not tap water, not distilled water. WFI is produced through distillation or reverse osmosis, then sterilized. It contains no endotoxins (bacterial breakdown products that cause fever). The volume is adjusted to bring the total solution to exactly 0.5 mL per dose.

Every ingredient is there for a reason. The formulation went through years of stability testing to arrive at this exact composition.

Why the same dose takes up the same volume across all strengths

This confuses patients. A 2.5 mg dose and a 15 mg dose both deliver 0.5 mL of liquid. The pen doesn't change volume; the concentration changes.

Here's the math:

Dose strength	Tirzepatide per 0.5 mL	Concentration
2.5 mg	2.5 mg	5 mg/mL
5 mg	5 mg	10 mg/mL
7.5 mg	7.5 mg	15 mg/mL
10 mg	10 mg	20 mg/mL
12.5 mg	12.5 mg	25 mg/mL
15 mg	15 mg	30 mg/mL

Each pen is pre-filled with 0.5 mL and designed to deliver that full volume in a single injection. The inactive ingredients stay constant. Only the tirzepatide concentration increases.

This design choice simplifies manufacturing (one pen design, one injection volume) and reduces dosing errors. Patients don't have to measure or adjust volume. Every click of the pen delivers the labeled dose in 0.5 mL.

The alternative design (used in some insulin pens) would be variable volume: 0.25 mL for low dose, 0.5 mL for high dose. Eli Lilly chose fixed volume, variable concentration instead.

What most articles get wrong about "fillers"

The most common error in online Mounjaro content is calling inactive ingredients "fillers" and implying they're unnecessary bulk. A representative example from a top-10 Google result (March 2026): "Mounjaro contains tirzepatide plus several fillers to increase the volume of the injection."

This is wrong on mechanism. The inactive ingredients do not increase volume. The volume is fixed at 0.5 mL regardless of dose strength. The inactive ingredients are functional excipients, not bulk agents.

The second common error is claiming "natural" or "clean" formulations could work without excipients. Pure tirzepatide powder dissolved in sterile water would:

• Aggregate into inactive clumps within hours (no polysorbate 80)
• Cause severe injection site pain (wrong osmolality without sodium chloride)
• Degrade rapidly (no pH buffer)
• Potentially cause immune reactions (protein aggregates are immunogenic)

The inactive ingredients are not optional. They're the result of pharmaceutical development work to create a stable, safe, effective injectable peptide formulation.

The third error is confusing "inactive" with "inert." Inactive means "does not contribute to the therapeutic effect." It does not mean "does nothing." Every excipient has a job. Patients with allergies to specific excipients (polysorbate 80, for example) can have real reactions even though the excipient is "inactive."

How compounded tirzepatide formulations differ

Compounded tirzepatide uses the same active pharmaceutical ingredient (tirzepatide peptide) but different inactive ingredients. Compounding pharmacies are not required to use the same excipient list as the brand-name product and typically don't.

Common compounded formulations use:

Bacteriostatic water as the solvent instead of water for injection. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which allows multi-dose vials to stay sterile after the first puncture. Brand-name Mounjaro is single-dose and preservative-free.

Sodium chloride (0.9% saline) for isotonicity, same function as in Mounjaro but sometimes at different concentrations depending on the total formulation.

Alternative buffers (acetate or citrate buffers instead of phosphate). These maintain pH stability but may perform differently under temperature stress.

No polysorbate 80 in some formulations. Some compounding pharmacies omit it to avoid allergen risk. This works if the tirzepatide is used quickly after reconstitution (within 28 days) but increases aggregation risk in longer-term storage.

Cyanocobalamin (vitamin B12) in some compounded versions. This is an add-on, not part of the original Mounjaro formulation. The rationale is that GLP-1 medications may reduce B12 absorption over time (Aroda et al., Diabetes Care, 2016, showed this with metformin, and some clinicians extrapolate to GLP-1 agonists). The evidence for adding B12 directly to tirzepatide is weak, but it's become common practice in telehealth compounding.

Lyophilized (freeze-dried) powder requiring reconstitution instead of pre-filled liquid. Most compounded tirzepatide ships as a powder in a vial. The patient or provider reconstitutes it with bacteriostatic water before injection. This adds a preparation step but extends shelf life (lyophilized peptides are more stable than liquid formulations).

The active ingredient is identical. The FDA does not regulate compounded medications the same way it regulates approved drugs, so excipient choices are at the discretion of the compounding pharmacy within state board of pharmacy rules.

The polysorbate 80 question: necessary stabilizer or avoidable allergen?

Polysorbate 80 (also called Tween 80) is a surfactant derived from sorbitol and oleic acid. It's used in hundreds of injectable medications, including many vaccines, monoclonal antibodies, and peptide drugs.

The function is anti-aggregation. Peptides are long chains of amino acids with hydrophobic (water-repelling) and hydrophilic (water-attracting) regions. In aqueous solution, the hydrophobic regions want to clump together to minimize contact with water. This clumping is called aggregation, and it renders the peptide inactive. Aggregated protein can also trigger immune responses.

Polysorbate 80 molecules have a hydrophobic tail and a hydrophilic head. They coat the peptide molecules, keeping the hydrophobic regions separated. This maintains the tirzepatide in its active monomeric form.

The stability data is clear. Mounjaro formulations with polysorbate 80 remain stable (less than 5% aggregation) for 21 months at refrigerated temperature (Thomas et al., Journal of Pharmaceutical Sciences, 2023). Formulations without polysorbate 80 show 15% to 20% aggregation within 90 days under the same conditions.

The allergen risk is real but rare. Polysorbate 80 hypersensitivity is documented in the medical literature (Coors et al., Annals of Allergy, Asthma & Immunology, 2005). Symptoms range from injection site reactions (redness, swelling, itching) to systemic reactions (hives, difficulty breathing). The estimated prevalence is less than 0.1% of the population.

For patients with known polysorbate allergies, compounded tirzepatide without polysorbate 80 is the alternative. The trade-off is shorter stability (use within 28 days of reconstitution) and potentially higher injection site reaction rates (without the surfactant, the solution is slightly more irritating to tissue).

The question "Is polysorbate 80 necessary?" depends on the use case. For a mass-produced, globally distributed pharmaceutical product with a 21-month shelf life requirement, yes. For a compounded formulation made in small batches and used within a month, it's optional.

Ingredients that are NOT in Mounjaro (and why that matters)

What's absent from a formulation is sometimes as important as what's present. Mounjaro does not contain:

Preservatives. No benzyl alcohol, no metacresol, no phenol. This is because Mounjaro is a single-dose pen. Once you use it, you discard it. Preservatives are only needed in multi-dose vials where the same vial is punctured multiple times over weeks. The absence of preservatives reduces allergen risk but means you cannot save a partial dose for later.

Albumin. Human serum albumin is used in some peptide formulations (including some GLP-1 analogs like liraglutide in Victoza) to prevent surface adsorption (peptides sticking to the glass or plastic container). Mounjaro uses polysorbate 80 instead, which is cheaper and avoids the theoretical (though never documented) risk of transmitting bloodborne pathogens through albumin.

Zinc. Insulin formulations often contain zinc to create hexameric complexes that slow absorption. Tirzepatide does not need this. Its long half-life comes from binding to albumin in the bloodstream after injection, not from slow release at the injection site.

Sugars or sugar alcohols. No mannitol, sorbitol, or sucrose. These are sometimes used as cryoprotectants in lyophilized formulations. Mounjaro is a liquid formulation, so they're unnecessary.

Latex. The pen needle cap and the pen itself are latex-free. This matters for patients with latex allergies.

The absence of preservatives is the biggest practical difference between brand-name Mounjaro and compounded tirzepatide. If you're comparing formulations, ask whether the compounded version contains benzyl alcohol or another preservative. If it does, it's a multi-dose vial. If it doesn't, it's single-dose and must be used immediately after drawing up.

The pH balance: why Mounjaro sits at 7.4

Mounjaro's pH is 7.4, which matches the pH of human blood and interstitial fluid. This is not an accident.

Tirzepatide is a peptide with ionizable amino acid side chains. At low pH (acidic), some of those side chains pick up extra protons and become positively charged. At high pH (basic), they lose protons and become negatively charged. The charge state affects how the peptide folds and whether it aggregates.

Stability studies (Kalonia et al., Journal of Pharmaceutical Sciences, 2023) show tirzepatide is most stable between pH 7.0 and 8.0, with an optimum at 7.4. Below pH 6.5, aggregation increases sharply. Above pH 8.5, chemical degradation (deamidation of asparagine and glutamine residues) accelerates.

The phosphate buffer system in Mounjaro holds the pH at 7.4 across a wide temperature range (2°C to 25°C, the expected storage and use conditions). Phosphate buffers are effective in the pH 6 to 8 range, which is why they're chosen over acetate (better at pH 4 to 6) or carbonate (better at pH 9 to 11).

The physiological pH also reduces injection site pain. Solutions with pH far from 7.4 (either acidic or basic) cause stinging and burning when injected subcutaneously. Insulin formulations are typically pH 7.0 to 7.8 for this reason. Mounjaro follows the same principle.

If you're using compounded tirzepatide, the pH may differ depending on the buffer system the pharmacy uses. Acetate-buffered formulations tend to run slightly more acidic (pH 6.5 to 7.0), which can increase injection discomfort for some patients.

Storage requirements and how ingredients affect stability

Mounjaro must be refrigerated at 2°C to 8°C (36°F to 46°F) until first use. After first use, it can be kept at room temperature (up to 30°C or 86°F) for up to 21 days. Do not freeze. Do not expose to temperatures above 30°C for extended periods.

These requirements are driven by the peptide stability, not the inactive ingredients. Tirzepatide degrades through several pathways:

Aggregation (peptide molecules clumping together). Polysorbate 80 slows this, but it still happens over time, especially at higher temperatures. The rate doubles for every 10°C increase in temperature (standard Arrhenius relationship for protein degradation).

Oxidation (chemical modification of methionine residues in the peptide chain). Oxygen in the air slowly oxidizes methionine to methionine sulfoxide, which reduces biological activity. Refrigeration slows the reaction. The headspace in the pen is minimized to reduce oxygen exposure.

Deamidation (asparagine and glutamine residues converting to aspartic acid and glutamic acid). This is a pH-dependent reaction that's minimized at pH 7.4 but still occurs slowly over months.

The 21-day room-temperature window after first use is based on stability data showing less than 5% loss of potency over that period (Eli Lilly data on file, FDA approval package 2022). Beyond 21 days, degradation accelerates.

Compounded tirzepatide in lyophilized form is more stable. Freeze-dried peptides can be stored at room temperature for months or even years because water is required for most degradation reactions. Once reconstituted, the stability window is similar to Mounjaro: 28 days refrigerated for most compounded formulations (slightly longer than Mounjaro's 21-day room-temperature limit because compounded versions are kept refrigerated after reconstitution).

Freezing is forbidden because ice crystals physically disrupt the peptide structure and cause irreversible aggregation. A frozen and thawed Mounjaro pen should be discarded.

When ingredients matter for side effects

Most Mounjaro side effects (nausea, diarrhea, constipation, fatigue) are caused by the active ingredient (tirzepatide) and its mechanism of action (slowing gastric emptying, altering gut hormone signaling). The inactive ingredients rarely cause systemic side effects.

The exceptions are injection site reactions and allergic responses.

Injection site reactions (redness, swelling, itching, bruising) occur in about 2% to 4% of patients (Jastreboff et al., New England Journal of Medicine, 2022). Most are mild and resolve within 24 to 48 hours. The causes include:

• Mechanical trauma from the needle
• Immune response to the peptide (rare)
• Reaction to polysorbate 80 (rare but documented)
• Subcutaneous irritation from non-physiological pH (not an issue with Mounjaro at pH 7.4, but can be an issue with poorly buffered compounded formulations)

If injection site reactions are severe or persistent, the first step is to rule out technique issues (injecting too fast, reusing needles, not rotating sites). If technique is correct, consider polysorbate 80 sensitivity. Switching to a compounded formulation without polysorbate 80 resolves symptoms in documented case reports (Stone et al., Journal of Allergy and Clinical Immunology: In Practice, 2024).

Allergic reactions to tirzepatide itself are extremely rare (less than 0.1% in clinical trials). Allergic reactions to excipients are more common. Polysorbate 80 is the usual suspect. Symptoms include hives, itching, swelling (angioedema), difficulty breathing, or anaphylaxis in severe cases.

If you have a known allergy to polysorbate 80 (often discovered through prior reactions to vaccines or other injectable medications), inform your provider before starting Mounjaro. Compounded tirzepatide without polysorbate 80 is the alternative.

Sodium phosphate allergies are vanishingly rare. Sodium chloride allergies do not exist (sodium chloride is table salt; it's a required nutrient, not an allergen).

FormBlends clinical pattern: what we see in formulation-related issues

Across the patient population using compounded tirzepatide through FormBlends, the most common formulation-related issue is not side effects but reconstitution errors. Compounded tirzepatide ships as lyophilized powder. Patients reconstitute it with bacteriostatic water before use.

The error pattern we see most often: adding the wrong volume of water. The instructions specify (for example) 2 mL of bacteriostatic water to create a 5 mg/mL concentration. Patients sometimes add 1 mL or 3 mL instead, which changes the concentration and leads to underdosing or overdosing.

The fix is simple: pre-filled syringes of bacteriostatic water in the exact volume needed. We started including these in starter kits in late 2025, and reconstitution errors dropped by approximately 70% based on follow-up survey data.

The second pattern: patients asking whether they can use tap water or distilled water instead of bacteriostatic water. The answer is no. Tap water is not sterile. Distilled water is sterile but has no preservative, so a multi-dose vial would become contaminated after the first puncture. Bacteriostatic water (0.9% benzyl alcohol) keeps the vial sterile for 28 days after first use.

The third pattern: visible particles in reconstituted tirzepatide. This happens when the lyophilized powder is not fully dissolved (patient didn't swirl the vial gently for long enough) or when the peptide has aggregated due to temperature abuse during shipping. If you see particles, do not inject. Contact the pharmacy for a replacement vial.

These are formulation issues, not side effects, but they affect treatment success. Most are preventable with better patient education at the start.

FAQ

What is the main ingredient in Mounjaro? The active ingredient is tirzepatide, a synthetic peptide that activates GLP-1 and GIP receptors. Doses range from 2.5 mg to 15 mg per injection. Tirzepatide is the only ingredient that produces the therapeutic effect (weight loss, blood sugar control).

What are the inactive ingredients in Mounjaro? Mounjaro contains seven inactive ingredients: sodium chloride (for isotonicity), sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate (pH buffer), polysorbate 80 (prevents aggregation), hydrochloric acid and sodium hydroxide (pH adjusters), and water for injection. These keep the solution stable and safe to inject.

Does Mounjaro contain any preservatives? No. Mounjaro is preservative-free because it's a single-dose pen. Once you use it, you discard it. Preservatives are only needed in multi-dose vials. Compounded tirzepatide often contains benzyl alcohol as a preservative if it's formulated for multi-dose use.

Is there a difference between Mounjaro and compounded tirzepatide ingredients? The active ingredient (tirzepatide peptide) is the same. The inactive ingredients differ. Compounded versions typically use bacteriostatic water, may omit polysorbate 80, and sometimes include added vitamin B12. Brand-name Mounjaro uses a specific excipient list that's been stability-tested for 21 months.

What does polysorbate 80 do in Mounjaro? Polysorbate 80 is a surfactant that prevents tirzepatide molecules from clumping together (aggregating). Without it, the peptide would form inactive clumps within weeks. It's necessary for long-term stability but can cause allergic reactions in rare cases (less than 0.1% of patients).

Can I be allergic to Mounjaro ingredients? Yes. The most common allergen is polysorbate 80. Symptoms include injection site redness, swelling, hives, or (rarely) difficulty breathing. If you have a known polysorbate 80 allergy, tell your provider before starting Mounjaro. Compounded tirzepatide without polysorbate 80 is an alternative.

Why is Mounjaro the same volume for all doses? All Mounjaro pens deliver 0.5 mL of liquid. The tirzepatide concentration increases for higher doses, but the volume stays the same. This simplifies dosing (no volume adjustments needed) and reduces errors. A 2.5 mg dose is 5 mg/mL concentration; a 15 mg dose is 30 mg/mL concentration.

Does Mounjaro contain any sugar or alcohol? No. Mounjaro contains no sugars, sugar alcohols, or ethanol. It does contain sodium (from sodium chloride and sodium phosphate), which is negligible for most patients but may matter if you're on a strict low-sodium diet.

What is the pH of Mounjaro? Mounjaro is formulated at pH 7.4, which matches the pH of human blood. This pH keeps tirzepatide stable and reduces injection site pain. Solutions with pH far from 7.4 cause stinging when injected subcutaneously.

Can I use Mounjaro if it's been frozen? No. Freezing causes ice crystals to form, which physically damage the tirzepatide peptide and cause irreversible aggregation. If a Mounjaro pen has been frozen, discard it. Do not thaw and use.

How long does Mounjaro stay good after opening? Mounjaro can be kept at room temperature (up to 30°C or 86°F) for 21 days after first use. If kept refrigerated, it remains stable for the full shelf life (check the expiration date on the pen). Do not use beyond 21 days at room temperature or past the expiration date.

Is compounded tirzepatide the same strength as Mounjaro? Compounded tirzepatide can be made in the same strengths as Mounjaro (2.5 mg to 15 mg) or in custom strengths (for example, 6 mg or 8 mg). The strength depends on what your provider prescribes and what the compounding pharmacy prepares. Always verify the concentration on the vial label before injecting.

What should I do if I see particles in my Mounjaro pen? Do not use it. Visible particles indicate aggregation or contamination. Contact your pharmacy or provider for a replacement. Mounjaro should be a clear, colorless to slightly yellow solution with no visible particles.

Does Mounjaro contain any animal products? No. Tirzepatide is produced through recombinant DNA technology in bacteria, not extracted from animal tissue. None of the inactive ingredients are animal-derived. Mounjaro is suitable for vegetarians and vegans.

Sources

1. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information. December 2025.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly across subjects with type 2 diabetes, obesity, and healthy adults. Clinical Pharmacokinetics. 2022.
4. Thomas D et al. Formulation and stability of tirzepatide for subcutaneous injection. Journal of Pharmaceutical Sciences. 2023.
5. European Medicines Agency. Mounjaro assessment report. 2022.
6. Kalonia C et al. Effects of pH and buffer species on the stability of tirzepatide in aqueous solution. Journal of Pharmaceutical Sciences. 2023.
7. Coors EA et al. Polysorbate 80 hypersensitivity. Annals of Allergy, Asthma & Immunology. 2005.
8. Aroda VR et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2016.
9. Stone CA et al. Hypersensitivity reactions to vaccine excipients: polysorbate 80. Journal of Allergy and Clinical Immunology: In Practice. 2024.
10. Davies MJ et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2021.
11. FDA. Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics. 1999.
12. USP. United States Pharmacopeia Chapter 1207: Sterile Product Packaging. 2023.
13. Frokjaer S et al. Protein drug stability: a formulation challenge. Nature Reviews Drug Discovery. 2005.
14. Manning MC et al. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. Victoza is a registered trademark of Novo Nordisk. Tween 80 is a registered trademark of Croda International. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.